NCT01909843View on ClinicalTrials.gov

ALX-0171 Safety Study in Adults With Hyperresponsive Airways

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Respiratory Syncytial Virus Infection
Interventions
BIOLOGICAL

ALX-0171

Escalating dose of ALX-0171 during maximum 3 consecutive days: from 2.1 mg to maximum 200 mg per inhaled dose followed by daily dose of 70 mg, 140 mg or 200 mg per dose for maximum 4 consecutive days

Trial Locations (1)

82131

Gauting

All Listed Sponsors
lead

Ablynx, a Sanofi company

INDUSTRY

NCT01909843 - ALX-0171 Safety Study in Adults With Hyperresponsive Airways | Biotech Hunter | Biotech Hunter